IMA
ImageneBio Inc
There isn't enough reported data to score IMA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
IMA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IMA PE Valuation
IMA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IMA Forward outlook
There aren't enough analyst estimates for IMA to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$8.19 | +$6.45 |
| Q2 2025 | -$7.80 | +$9.12 |
| Q1 2025 | -$10.44 | +$8.40 |
| Q4 2024 | -$12.24 | +$7.32 |
| Q3 2024 | -$14.64 | +$4.68 |
| Q2 2024 | -$16.92 | +$3.36 |
| Q1 2024 | -$18.84 | +$3.00 |
| Q4 2023 | -$19.56 | +$3.24 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 156% for IMA versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
IMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $659K | -88% |
| Q3 2023 | $1.2M | -81% |
| Q2 2023 | $2M | +425% |
| Q1 2023 | $5.3M | +57% |
| Q4 2022 | $5.5M | -73% |
| Q3 2022 | $6.4M | +71% |
| Q2 2022 | $382K | -89% |
| Q1 2022 | $3.4M | -2.6% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for IMA versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -3324% | -3047 points |
| Q3 2023 | -1646% | -1367 points |
| Q2 2023 | -923% | +4562 points |
| Q1 2023 | -292% | +209 points |
| Q4 2022 | -277% | -291 points |
| Q3 2022 | -279% | +108 points |
| Q2 2022 | -5485% | -5127 points |
| Q1 2022 | -501% | -221 points |
IMA's operating margin was −3324% last quarter, down 3047 points from the same quarter a year ago, near the bottom of its range since 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
IMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | +$17.1M |
| Q2 2026 | -$9.1M | -$5.7M |
| Q1 2026 | -$14.8M | -$4.2M |
| Q4 2023 | -$22.1M | -$4.2M |
| Q3 2023 | -$20M | -$1.6M |
| Q2 2023 | -$18.1M | +$1.3M |
| Q1 2023 | -$19.9M | -$119K |
| Q4 2022 | -$17.9M | -$4M |
IMA has burned cash in almost every quarter: −$41M over the past year, against −$63M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IMA on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.9% | +961K shares |
| 1 year | +326% | +13.1M shares |
| 3 years | +423% | +13.8M shares |
IMA has 17M diluted shares, up 326% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IMA Net Leverage
IMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.2 | Oversold |
| Stochastic | 6.5 | Oversold |
IMA's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IMA PE vs Healthcare Sector
| Metric | IMA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IMA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.18 | 17% below |
| 20 week MA | $4.95 | 30% below |
| 50 week MA | $5.63 | 39% below |
| 100 week MA | $9.77 | 65% below |
| 200 week MA | $23.0 | 85% below |
IMA is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IMA on trend strength, trading above more of its moving averages.
IMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $384.0 | $178.1 | -54% |
| 2022 | $178.1 | $34.2 | -81% |
| 2023 | $34.2 | $23.6 | -31% |
| 2024 | $23.6 | $18.5 | -22% |
| 2025 | $18.5 | $5.80 | -69% |
| 2026 YTD | $5.80 | $3.45 | -41% |
IMA has finished every year since 2021 lower, and it's down 41% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IMA on returns for 2026, with the stronger performance.